Search results for "CV"

showing 10 items of 904 documents

HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals

2017

Anecdotal reports suggest that patients with chronic hepatitis C virus (HCV) hepatitis and overt or occult hepatitis B virus (HBV) coinfection may reactivate HBV when HCV is suppressed or cleared by direct-acting antivirals (DAAs). We assessed the prevalence of overt or previous HBV coinfection and the risk of HBV reactivation in patients with HCV cirrhosis treated with DAAs. This was a retrospective cohort of 104 consecutive patients with HCV cirrhosis treated with DAAs. Serum HCV-RNA and HBV-DNA were tested at weeks 4, 8 and 12 of DAAs therapy and at week 12 of follow-up. At the start of DAAs, eight patients (7.7%) were HBsAg positive/HBeAg negative with undetectable HBV-DNA and low level…

AdultLiver CirrhosisMaleHepatitis B virusHBsAgCirrhosisHepacivirusHepacivirusmedicine.disease_causeAntiviral AgentsVirus03 medical and health sciencesHepatitis B Chronic0302 clinical medicineVirologymedicineHumansHBV-DNA reactivationnucleos(t)ide analogues therapyAgedRetrospective StudiesHepatitisHepatitis B virusHepatologybiologyCoinfectionbusiness.industryvirus diseasesRetrospective cohort studyHepatitis C ChronicMiddle Agedmedicine.diseasebiology.organism_classificationVirologyprevious HBV infectiondigestive system diseasesInfectious DiseasesHBV/HCV coinfection030220 oncology & carcinogenesisDNA ViralCoinfectionRNA ViralFemaleVirus Activation030211 gastroenterology & hepatologysustained virological responsebusiness
researchProduct

The burden of HBV infection in HCV patients in Italy and the risk of reactivation under DAA therapy

2019

Background: There is increasing awareness of HBV reactivation in HCV-RNA-positive/HBV-coinfected patients with chronic liver disease (CLD) treated with oral direct-acting antivirals (DAAs). Aim: To provide figures on the prevalence of HBV markers in HCV-RNA-positive subjects in Italy, where these findings are lacking. Methods: All subjects aged ≥18 years with CLD consecutively referring to Italian liver units located throughout country were prospectively enrolled in two national surveys in 2001 and 2014. Results: The total number of HCV-RNA-positive cases was 6984; 356 (5.1%) subjects vaccinated against HBV were excluded. A total of 6628 cases were evaluated. The prevalence rates of HBsAg, …

AdultLiver CirrhosisMaleHepatitis B virusmedicine.medical_specialtyHBsAgCirrhosisHBV reactivationHbv markersHbv reactivationPrevalenceHbv vaccinationHepacivirusChronic liver diseaseAntiviral Agents03 medical and health sciences0302 clinical medicineInternal medicinePrevalencemedicineHumansHepatitis B AntibodiesReimbursementAgedHepatitis B Surface AntigensHepatologyCoinfectionbusiness.industryGastroenterologyHCV therapyvirus diseasesHepatitis C ChronicMiddle AgedHepatitis Bmedicine.diseaseChronic HCV infection; HBV reactivation; HBV/HCV coinfection; HCV therapydigestive system diseasesHBV/HCV coinfectionItalyChronic HCV infection030220 oncology & carcinogenesisDNA ViralFemaleVirus Activation030211 gastroenterology & hepatologybusiness
researchProduct

The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C.

2007

Aims To assess whether host metabolic factors influence the degree of hepatic steatosis and fibrosis in patients infected with hepatitis C virus, and to evaluate the impact of anti-viral therapy on insulin resistance and serum levels of adipocytokines. Methods Clinical and biochemical features, anthropometrical characteristics, and levels of fasting insulin, leptin, adiponectin and resistin were measured in ‘naı¨ve’ patients with chronic hepatitis C, before, during and after therapy with Peg-Interferon-alpha 2a plus Ribavirin. Results Forty-eightpatientswereincluded(M/F28/20;meanage50.0 12.6years; 62.5% genotype-1). Body mass index was 26.4 4.0 kg/m2 , and visceral obesity was present in 24…

AdultLiver CirrhosisMaleInterferon-alphahcv steatosisHepatitis C ChronicInterferon alpha-2Intra-Abdominal FatMiddle AgedAntiviral AgentsRecombinant ProteinsFatty LiverRibavirinAdipocytesHumansFemaleObesityInsulin ResistanceAlimentary pharmacologytherapeutics
researchProduct

Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients.

2013

Background & Aims: Unhealthy food intake, specifically fructose, has been associated with metabolic alterations and with the severity of liver fibrosis in patients with non-alcoholic fatty liver disease. In a cohort of patients with genotype 1 chronic hepatitis C (G1 CHC), we tested the association of fructose intake with the severity of liver histology. Methods: Anthropometric and metabolic factors, including waist circumference (WC), waist-to-hip ratio (WHR), dorso-cervical lipohypertrophy and HOMA were assessed in 147 consecutive biopsy-proven G1 CHC patients. Food intake, namely industrial and fruit fructose, was investigated by a three-day structured interview and a computed database. …

AdultLiver CirrhosisMalePathologymedicine.medical_specialtyGenotypeHepatitis C virusLIVER FIBROSISmedicine.disease_causeGastroenterologychemistry.chemical_compoundWaist–hip ratioHcv fructose fibrosisInternal medicineFRUCTOSEmedicineHumansIndustryAgedSettore MED/12 - GastroenterologiaHepatologybusiness.industryFatty liverLipohypertrophyFructoseHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseasechemistryFruitFemaleSteatosisSteatohepatitishepatitis Cbusiness
researchProduct

Geographical pattern of chronic liver diseases in Italy: Results from two pooled national surveys

2019

Background: The information on the geographical characteristics of chronic liver diseases (CLD) in Italy is out-dated. Aim: To provide up-dated information on the geographical pattern of patients with CLD born in Italy. Methods: Patients with CLD were enrolled in two national surveys performed in 2001 and 2014, which prospectively recruited subjects aged ≥18 years referring to Italian liver units located throughout the country that apply a similar clinical approach and analytical methods. Results: The total number of patients enrolled was 11,676. Alcohol-related CLD was more frequently observed in northern/central areas (25.0% vs. 20.7%, p < .001), while HBV-related (15.4% vs. 13.3%, p =…

AdultLiver CirrhosisMalecongenital hereditary and neonatal diseases and abnormalitiesAlcohol; Chronic hepatitis; Geographical pattern; HBV; HCV; Liver cirrhosisLiver cirrhosiGeographical patternHepatitis B ChronicChronic hepatitisSurveys and QuestionnairesEnvironmental healthHBVInternal MedicineHumansMedicineLiver Diseases AlcoholicChronic hepatitisAgedGeographybusiness.industryLiver DiseaseLiver DiseasesHepatitis C ChronicMiddle Agedrespiratory tract diseasesItalyChronic DiseaseHCVChronic hepatitiFemalebusinessAlcoholHuman
researchProduct

Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C.

2005

Conflicting data exist regarding the relationship between hepatitis C virus genotype 1 and hepatic steatosis as well as the latter's role in the progression of fibrosis and treatment response. We assessed factors associated with hepatic steatosis in genotype 1 chronic hepatitis C and the impact of hepatic fat on fibrosis development and interferon responsiveness. Two hundred ninety-one non-diabetic patients with genotype 1 chronic hepatitis C were examined for the presence of steatosis and its correlation with clinical, virological, and biochemical data, including insulin resistance (IR), evaluated by the homeostasis model assessment (HOMA) score. Steatosis was graded as mild (1%-20% of hep…

AdultLiver CirrhosisMalemedicine.medical_specialtyAdolescentGenotypeHepacivirusGastroenterologyBody Mass IndexInsulin resistanceSex FactorsFibrosisRisk FactorsInternal medicinemedicineHumansRisk factorAgedHepatologybusiness.industryHCV steatosi insulinoresistenzaHepatitis COdds ratiogamma-GlutamyltransferaseHepatitis C ChronicMiddle Agedmedicine.diseaseFatty LiverEndocrinologyMultivariate AnalysisFemaleSteatosisMetabolic syndromeInsulin ResistancebusinessBody mass indexHepatology (Baltimore, Md.)
researchProduct

Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication

2017

Background & Aims: The risk of hepatocellular carcinoma (HCC) is reduced but not eradicated among patients with hepatitis C virus (HCV)-induced advanced hepatic fibrosis who attained sustained viral response (SVR). We aimed to assess the risk of cirrhosis-related complications in this specific group of patients. Methods: Data from previously reported Western cohort studies including patients with chronic HCV infection and bridging fibrosis or cirrhosis who attained SVR were pooled for survival analyses on the individual patient level. The primary endpoint was HCC and the secondary endpoint was clinical disease progression, defined as liver failure, HCC or death. Results: Included were 1…

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosisCarcinoma HepatocellularSustained Virologic ResponseHepatitis C virusmedicine.disease_causeGastroenterologyCohort Studies03 medical and health sciencesLiver disease0302 clinical medicineSDG 3 - Good Health and Well-beingRisk FactorsDiabetes mellitusInternal medicinemedicineClinical endpointHumansAgedProportional Hazards ModelsRetrospective StudiesHepatologybusiness.industryIncidenceLiver NeoplasmsRetrospective cohort studyHepatitis C ChronicMiddle Agedmedicine.diseasedigestive system diseases030220 oncology & carcinogenesisHepatocellular carcinomaHCVDisease Progression030211 gastroenterology & hepatologyFemalebusinessLiver cancer
researchProduct

Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatit…

2011

Transient elastography (TE) is adequate for a diagnosis of cirrhosis, but its accuracy for milder stages of fibrosis is much less satisfactory. The objective of this study was to compare the performance and the discordance rate of acoustic radiation force impulse (ARFI) and TE with liver biopsy in a cohort of chronic hepatitis C (CHC) patients.One hundred thirty-nine consecutive patients with CHC were enrolled in two tertiary centers, and evaluated for histological (Metavir score) and biochemical features. All patients underwent TE and ARFI.TE was unreliable in nine patients (6.5%), while in no cases (0%) were ARFI invalid measurements recorded (P=0.029). By area under receiver operating ch…

AdultLiver CirrhosisMalemedicine.medical_specialtyHepacivirusLiver fibrosisBiopsyHepacivirusImpulse (physics)behavioral disciplines and activitiesCohort StudiesElasticity Imaging TechniquesBiopsyotorhinolaryngologic diseasesMedicineHumansProspective StudiesAcoustic radiation forceAgedHepatologybiologymedicine.diagnostic_testbusiness.industryarfi fibroscan hcv fibrosisGastroenterologyReproducibility of ResultsHepatitis CHepatitis C ChronicMiddle Agedbiology.organism_classificationmedicine.diseaseROC CurveElasticity Imaging TechniquesRNA ViralFemalesense organsRadiologyTransient elastographybusinesspsychological phenomena and processes
researchProduct

Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population.

2016

Background & Aims: Life expectancy of patients with compensated hepatitis C virus (HCV) cirrhosis achieving sustained virologic response (SVR) is limited by liver events as compared to the general population. Thus, survival benefit of SVR remains to be measured. Methods: The study includes prospective surveillance data from three cohorts of Italian patients with compensated HCV cirrhosis who achieved SVR on an interferon-based (IFN) regimen, compared to simultaneously observed non-SVR, untreated and decompensated patients. Overall survival was calculated from the date of start of IFN to death. The number of deaths expected during the at-risk period was determined by applying age- and se…

AdultLiver CirrhosisMalemedicine.medical_specialtySustained Virologic ResponsePopulation03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansProspective StudieseducationSurvival analysisAgededucation.field_of_studyHepatologybusiness.industryMortality rateHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseSurgerySurvival RateRegimenStandardized mortality ratio030220 oncology & carcinogenesisRelative riskHCVFemale030211 gastroenterology & hepatologyInterferonsViral hepatitisbusiness
researchProduct

Peginterferon-Α_2B plus ribavirin is more effective than peginterferon-Α_2A plus ribavirin in menopausal women with chronic hepatitis C.

2012

Under-enrolment of women to randomized clinical trials, including chronic hepatitis C, has long been recognized. The aim of this study was to identify factors predictive of sustained virological response (SVR) to PEG IFN/Ribavirin antiviral therapy in relation to gender and reproductive status of female patients involved. Seven hundred and forty-six treatment-naïve patients (431 men, 315 women) treated with Peg-IFNα-2a (180 μg/week) or Peg-IFNα-2b (1.5 μg/kg/week) plus ribavirin (800–1400 mg/day) for 24 or 48 weeks were studied between 2006 and 2010. Differences in SVR rate, overall and by gender were assessed after adjustment and propensity score matching. SVR was obtained in 44.2% of Peg-…

AdultMaleAdolescentInterferon alpha-2Antiviral AgentsPolyethylene GlycolsYoung AdultSex FactorsRibaviringenderHumansAgedSettore MED/12 - GastroenterologiaPeg IFNAge FactorsInterferon-alphaHepatitis C ChronicMiddle Agedcentral fat distribution cytokines metabolic syndrome pharmacokinetics sustained virological responseRecombinant ProteinsTreatment OutcomeDrug Therapy CombinationFemaleEpatite HCV; Peg IFN; genderMenopauseSettore SECS-S/01 - StatisticaEpatite HCVJournal of viral hepatitis
researchProduct